Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-33

But the view of the market is that this company was already generating this revenue level without the 30 channels now in place.

$300,000USD in revenue is tiddly winks to what they should now be generating per quarter based on the number of distributors they have and the clearance of Febridx in 2023.

Further, this is not being capped anymore. PVM are gone and there is no one to cap this - what would be the point in capping this anymore? People have had and still now have the opportunity to accumulate this at a very low price. The share price dropping today is solely off poor revenue for the product as it was sold to be robust and good uptake. Its simply not and those with the 10+Million shares agree.